当前位置：
X-MOL 学术
›
Diabetes Technol. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study
Diabetes Technology & Therapeutics ( IF 5.7 ) Pub Date : 2022-01-31 , DOI: 10.1089/dia.2021.0182 Satish K Garg 1 , David Liljenquist 2 , Bruce Bode 3 , Mark P Christiansen 4 , Timothy S Bailey 5 , Ronald L Brazg 6 , Douglas S Denham 7 , Anna R Chang 8 , Halis Kaan Akturk 1 , Andrew Dehennis 9 , Katherine S Tweden 9 , Francine R Kaufman 9
Diabetes Technology & Therapeutics ( IF 5.7 ) Pub Date : 2022-01-31 , DOI: 10.1089/dia.2021.0182 Satish K Garg 1 , David Liljenquist 2 , Bruce Bode 3 , Mark P Christiansen 4 , Timothy S Bailey 5 , Ronald L Brazg 6 , Douglas S Denham 7 , Anna R Chang 8 , Halis Kaan Akturk 1 , Andrew Dehennis 9 , Katherine S Tweden 9 , Francine R Kaufman 9
Affiliation
Background: Use of continuous glucose monitoring (CGM) systems is being rapidly adopted as standard of care for insulin-requiring patients with diabetes. The PROMISE study (NCT03808376) evaluated the accuracy and safety of the next-generation implantable Eversense CGM system for up to 180 days.
中文翻译：
评估下一代长达 180 天的长期植入式 Eversense 连续血糖监测系统的准确性和安全性：PROMISE 研究
背景：使用连续血糖监测 (CGM) 系统正迅速被用作需要胰岛素的糖尿病患者的护理标准。PROMISE 研究 (NCT03808376) 评估了下一代植入式 Eversense CGM 系统长达 180 天的准确性和安全性。
更新日期：2022-02-11
中文翻译：
评估下一代长达 180 天的长期植入式 Eversense 连续血糖监测系统的准确性和安全性：PROMISE 研究
背景：使用连续血糖监测 (CGM) 系统正迅速被用作需要胰岛素的糖尿病患者的护理标准。PROMISE 研究 (NCT03808376) 评估了下一代植入式 Eversense CGM 系统长达 180 天的准确性和安全性。
京公网安备 11010802027423号